Pfizer Inc. and Teva Pharmaceutical Industries Ltd. failed to oust a large antitrust lawsuit alleging they illegally worked to block generic competition to Pfizer blockbuster psychiatric drug Effexor XR.
Federal patent law doesn’t block allegations based on state law that Wyeth Pharmaceuticals Inc., since acquired by Pfizer, improperly acquired three patents covering Effexor XR and engaged in sham litigation with Teva to forestall generic competition, a federal judge ruled Sept. 19. Employee welfare benefit plans, insurers, and individual end payers alleged violations of antitrust and consumer protection laws in their respective states.
The decision reflects the impact of an 2017 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.